Skip to Content
Merck
  • Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency.

Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency.

The Journal of clinical investigation (2015-10-13)
Jolan E Walter, Lindsey B Rosen, Krisztian Csomos, Jacob M Rosenberg, Divij Mathew, Marton Keszei, Boglarka Ujhazi, Karin Chen, Yu Nee Lee, Irit Tirosh, Kerry Dobbs, Waleed Al-Herz, Morton J Cowan, Jennifer Puck, Jack J Bleesing, Michael S Grimley, Harry Malech, Suk See De Ravin, Andrew R Gennery, Roshini S Abraham, Avni Y Joshi, Thomas G Boyce, Manish J Butte, Kari C Nadeau, Imelda Balboni, Kathleen E Sullivan, Javeed Akhter, Mehdi Adeli, Reem A El-Feky, Dalia H El-Ghoneimy, Ghassan Dbaibo, Rima Wakim, Chiara Azzari, Paolo Palma, Caterina Cancrini, Kelly Capuder, Antonio Condino-Neto, Beatriz T Costa-Carvalho, Joao Bosco Oliveira, Chaim Roifman, David Buchbinder, Attila Kumanovics, Jose Luis Franco, Tim Niehues, Catharina Schuetz, Taco Kuijpers, Christina Yee, Janet Chou, Michel J Masaad, Raif Geha, Gulbu Uzel, Rebecca Gelman, Steven M Holland, Mike Recher, Paul J Utz, Sarah K Browne, Luigi D Notarangelo
ABSTRACT

Patients with mutations of the recombination-activating genes (RAG) present with diverse clinical phenotypes, including severe combined immune deficiency (SCID), autoimmunity, and inflammation. However, the incidence and extent of immune dysregulation in RAG-dependent immunodeficiency have not been studied in detail. Here, we have demonstrated that patients with hypomorphic RAG mutations, especially those with delayed-onset combined immune deficiency and granulomatous/autoimmune manifestations (CID-G/AI), produce a broad spectrum of autoantibodies. Neutralizing anti-IFN-α or anti-IFN-ω antibodies were present at detectable levels in patients with CID-G/AI who had a history of severe viral infections. As this autoantibody profile is not observed in a wide range of other primary immunodeficiencies, we hypothesized that recurrent or chronic viral infections may precipitate or aggravate immune dysregulation in RAG-deficient hosts. We repeatedly challenged Rag1S723C/S723C mice, which serve as a model of leaky SCID, with agonists of the virus-recognizing receptors TLR3/MDA5, TLR7/-8, and TLR9 and found that this treatment elicits autoantibody production. Altogether, our data demonstrate that immune dysregulation is an integral aspect of RAG-associated immunodeficiency and indicate that environmental triggers may modulate the phenotypic expression of autoimmune manifestations.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine, ≥99%
Sigma-Aldrich
Sulfuric acid, 99.999%
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine, ≥98% (TLC)
Sigma-Aldrich
TWEEN® 20, viscous liquid, suitable for cell culture
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine, ≥98.0% (NT)
Sigma-Aldrich
Sulfuric acid, ACS reagent, 95.0-98.0%
Sigma-Aldrich
Sulfuric acid, puriss., meets analytical specification of Ph. Eur., BP, 95-97%
Sigma-Aldrich
Deoxyribonucleic acid from calf thymus, Type XV, Activated, lyophilized powder
Sigma-Aldrich
3,3′,5,5′-Tetramethylbenzidine, tablet, 1 mg substrate per tablet
Sigma-Aldrich
Sulfuric acid solution, puriss. p.a., ≥25% (T)
Sigma-Aldrich
Sulfuric acid, puriss. p.a., for determination of Hg, ACS reagent, reag. ISO, reag. Ph. Eur., 95.0-97.0%
Sigma-Aldrich
Sulfuric acid, AR, ≥98%
Sigma-Aldrich
Sulfuric acid, LR, ≥98%
Sigma-Aldrich
Deoxyribonucleic acid, single stranded from calf thymus, lyophilized powder
Sigma-Aldrich
Phosphate buffered saline, Autoclaved, pH 7.2 (25 °C)
Sigma-Aldrich
6-Phosphonohexanoic acid, 97%